Non Hodgkin Lymphoma Clinical Trial

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma

Summary

The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Pathologically confirmed high-risk recurrent/relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL), after non-response to or failure of first-line standard therapy prior to high-dose chemotherapy/autologous stem cell transplant (HDCT/ASCT)
Pathologically confirmed high-risk, R/R non-Hodgkin lymphoma (NHL) after failure or non-response to first-line therapy, including but not limited to diffuse large B-cell lymphoma (DLBCL), anaplastic large cell lymphoma (ALCL) and primary mediastinal B-cell lymphoma
Pathologically confirmed recurrent cHL or NHL
Must have measurable [18F]fluorodeoxyglucose-positron emission tomography-computed tomography (FDG-PET-CT) positive disease in both cHL and NHL cohorts

Exclusion Criteria:

Prior treatment with an anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways, with the exception of anti-PD(L)-1 targeted therapies
Prior treatment with lymphocyte activation gene-3 (LAG-3)-targeted agents
Prior autologous stem cell transplantation (HDCT/ASCT)
History of allogeneic bone marrow transplantation and with active graft versus host disease (GVHD) and prior history of Grade > 2 GVHD

Other protocol-defined inclusion/exclusion criteria apply

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

68

Study ID:

NCT05255601

Recruitment Status:

Recruiting

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 54 Locations for this study

See Locations Near You

Local Institution
Phoenix Arizona, 85016, United States More Info
Site 0024
Contact
Nemours Childrens Hospital
Wilmington Delaware, 19803, United States More Info
Emi Caywood, Site 0061
Contact
302-651-5500
Local Institution
Orlando Florida, 32804, United States More Info
Site 0017
Contact
Local Institution
West Palm Beach Florida, 33407, United States More Info
Site 0027
Contact
Local Institution
Minneapolis Minnesota, 55454, United States More Info
Site 0025
Contact
Local Institution
Jackson Mississippi, 39216, United States More Info
Site 0020
Contact
Local Institution
Saint Louis Missouri, 63110, United States
Local Institution
Bronx New York, 10467, United States
$Form.Name
New York New York, 10032, United States More Info
Nobuko Hijiya, Site 0060
Contact
773-880-4562
Local Institution
Valhalla New York, 10595, United States More Info
Site 0059
Contact
Local Institution
Hershey Pennsylvania, 17033, United States More Info
Site 0019
Contact
Vanderbilt-Ingram Cancer Center
Nashville Tennessee, 37232, United States More Info
Debra Friedman, Site 0014
Contact
615-936-1762
Local Institution
Austin Texas, 78723, United States More Info
Site 0029
Contact
Local Institution
San Antonio Texas, 78207, United States More Info
Site 0026
Contact
Local Institution - 0037
Randwick New South Wales, 2031, Australia More Info
Site 0037
Contact
Local Institution - 0039
South Brisbane Queensland, 4101, Australia More Info
Site 0039
Contact
Local Institution
Nedlands Western Australia, 6009, Australia More Info
Site 0042
Contact
Local Institution - 0063
Angers , 49933, France More Info
Site 0063
Contact
Local Institution
Bordeaux , 33076, France More Info
Site 0048
Contact
Local Institution
Lyon , 69373, France More Info
Site 0021
Contact
Local Institution
Montpellier , 34295, France More Info
Site 0018
Contact
Local Institution
Paris , 75019, France More Info
Site 0047
Contact
Local Institution - 0006
Paris , 75571, France More Info
Site 0006
Contact
Local Institution - 0022
Rennes , 35203, France
Local Institution
Strasbourg , 67098, France More Info
Site 0052
Contact
Local Institution
Aachen , 52074, Germany
Local Institution
Berlin , 13353, Germany More Info
Site 0015
Contact
Local Institution
Giessen , 35392, Germany More Info
Site 0028
Contact
Local Institution
Muenster , 48149, Germany More Info
Site 0008
Contact
Local Institution
Munich , 80337, Germany More Info
Site 0051
Contact
Local Institution
Aviano , 33081, Italy More Info
Site 0010
Contact
Local Institution
Bologna , 40138, Italy More Info
Site 0007
Contact
Local Institution
Florence , 50139, Italy More Info
Site 0040
Contact
Local Institution
Genoa , 16147, Italy
Local Institution
Milano , , Italy More Info
Site 0001
Contact
Local Institution
Monza , 20900, Italy More Info
Site 0043
Contact
Local Institution
Napoli , 80131, Italy
Local Institution
Pavia , 27100, Italy More Info
Site 0041
Contact
Local Institution
Roma , 165, Italy More Info
Site 0002
Contact
Local Institution
Turin , 10126, Italy More Info
Site 0004
Contact
Local Institution
Utrecht , 3584 , Netherlands More Info
Site 0057
Contact
Local Institution
Barcelona , 8026, Spain
Local Institution
Barcelona , 8035, Spain More Info
Site 0046
Contact
Local Institution
Madrid , 28009, Spain More Info
Site 0030
Contact
Local Institution
Madrid , 28027, Spain More Info
Site 0058
Contact
Local Institution
Madrid , 28040, Spain More Info
Site 0044
Contact
Local Institution
Madrid , 28041, Spain More Info
Site 0055
Contact
Local Institution - 0045
Madrid , 28046, Spain More Info
Site 0045
Contact
Local Institution
Santander , 39008, Spain
Local Institution
Sevilla , 41013, Spain More Info
Site 0023
Contact
Local Institution
Valencia , , Spain More Info
Site 0049
Contact
Local Institution - 0050
Bristol Somerset, BS2 8, United Kingdom More Info
Site 0050
Contact
Local Institution - 0031
Birmingham West Midlands, B4 6N, United Kingdom
Local Institution
London , NW1 2, United Kingdom More Info
Site 0054
Contact
Local Institution
Nottingham , NG5 1, United Kingdom More Info
Site 0003
Contact
Local Institution
Sutton , SM2 5, United Kingdom More Info
Site 0053
Contact

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

68

Study ID:

NCT05255601

Recruitment Status:

Recruiting

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.